Worldwide, 400 million individuals suffer from allergic rhinitis, the most prevalent type of allergy that includes hay fever and allergies to things such as mould, plants, dust and animal dander.1 The topical nasal allergy market is currently estimated to be worth some US$2.5bn annually, and the number of sufferers shows no signs of diminishing, leading to the continuing search for medication to alleviate symptoms.2
The current treatment of choice for many sufferers, particularly those who wish to avoid systemic medication, is the aqueous pump spray containing corticosteroid active pharmaceutical ingredients (APIs) such as fluticasone propionate, mometasone furoate monohydrate, and beclometasone dipropionate. These ‘wet’ sprays have become widely used since chlorofluorocarbon (CFC) propellants were phased out of use in the 1990s, halting the marketing of the previously popular ‘dry’ nasal Metered Dose Inhalers (MDIs).
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.